Oxford BioDynamics PLC Publication of Annual Report and Notice of AGM (6492A)

TIDMOBD

RNS Number : 6492A

Oxford BioDynamics PLC

23 January 2020

23 January 2020

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Publication of 2019 Annual Report and Accounts and Notice of AGM

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of biomarkers based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that copies of its annual report and accounts for the year ended 30 September 2019 (incorporating the Notice of Annual General Meeting) ("Annual Report") have been posted to shareholders. An electronic copy of the Annual Report will be available on its website at www.oxfordbiodynamics.com, within the Investor Relations section.

Notice of Annual General Meeting

The Company's Annual General Meeting will be held at The Kloppenberg Room, Cohen Quad, Exeter College, Walton Street, Oxford, OX1 2HE, on 20 March 2020 at 11.00 am.

-ENDS-

For further details please contact:

 
 Oxford BioDynamics Plc 
  Christian Hoyer Millar, 
  CEO 
  Paul Stockdale, CFO              [phone] 
 Shore Capital 
  Nominated Advisor and Broker 
  Stephane Auton 
  Edward Mansfield                [phone] 
 
   FTI Consulting 
   Financial Public Relations 
   Adviser 
   Natalie Garland-Collins        [phone] 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NOAFLFFDLDIFFII

(END) Dow Jones Newswires

January 23, 2020 02:00 ET (07:00 GMT)